2023-11-01 2024-10-31 false No description of principal activity Debitam - Tax and Accounts 1.0 11644460 bus:FullAccounts 2023-11-01 2024-10-31 11644460 bus:Micro-entities 2023-11-01 2024-10-31 11644460 bus:AuditExempt-NoAccountantsReport 2023-11-01 2024-10-31 11644460 bus:SmallCompaniesRegimeForAccounts 2023-11-01 2024-10-31 11644460 bus:PrivateLimitedCompanyLtd 2023-11-01 2024-10-31 11644460 2023-11-01 2024-10-31 11644460 2024-10-31 11644460 bus:RegisteredOffice 2023-11-01 2024-10-31 11644460 core:WithinOneYear 2024-10-31 11644460 core:AfterOneYear 2024-10-31 11644460 2022-11-01 11644460 bus:Director1 2023-11-01 2024-10-31 11644460 bus:Director1 2024-10-31 11644460 bus:Director1 2022-11-01 2023-10-31 11644460 bus:CompanySecretary1 2023-11-01 2024-10-31 11644460 bus:LeadAgentIfApplicable 2023-11-01 2024-10-31 11644460 2022-11-01 2023-10-31 11644460 2023-10-31 11644460 core:WithinOneYear 2023-10-31 11644460 core:AfterOneYear 2023-10-31 11644460 bus:EntityAccountantsOrAuditors 2022-11-01 2023-10-31 11644460 core:ComputerEquipment 2023-11-01 2024-10-31 11644460 core:ComputerEquipment 2024-10-31 11644460 core:ComputerEquipment 2023-10-31 11644460 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2024-10-31 11644460 core:LeasedAssetsHeldAsLessee core:PlantMachinery 2023-10-31 11644460 core:CostValuation core:Non-currentFinancialInstruments 2024-10-31 11644460 core:CostValuation core:Non-currentFinancialInstruments 2023-10-31 11644460 core:AdditionsToInvestments core:Non-currentFinancialInstruments 2024-10-31 11644460 core:DisposalsDecreaseInInvestments core:Non-currentFinancialInstruments 2024-10-31 11644460 core:RevaluationsIncreaseDecreaseInInvestments core:Non-currentFinancialInstruments 2024-10-31 11644460 core:Non-currentFinancialInstruments 2024-10-31 11644460 core:Non-currentFinancialInstruments 2023-10-31 iso4217:GBP xbrli:shares xbrli:pure
Registered Number: 11644460
England and Wales

 

 

 


Report of the Director and Unaudited Financial Statements

for the year ended 31 October 2024

for

PHARMAKON ADVANCES LTD

 
 
 
£
2024
£
   
£
2023
£
Fixed assets 597  895 
Current assets 128,837  163,288 
Creditors: amount falling due within one year (121,234) (113,801)
Net current assets 7,603  49,487 
Total assets less current liabilities 8,200  50,382 
Net assets 8,200  50,382 
 
Capital and reserves 8,200  50,382 
 
  1. For the year ended 31 October 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
  2. The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476 of the companies act 2006.
  3. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts
The accounts have been prepared in accordance with the micro-entity provisions and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

Signed on behalf of the board of directors:


----------------------------------
Malika Salhi
Director

Date approved: 10 January 2025
1
Statutory Information
PHARMAKON ADVANCES LTD is a private limited company, limited by shares, domiciled in England and Wales, registration number 11644460, registration address 14 Warwick House, Windsor Way, London, England, W14 0UQ, United Kingdom.

The presentation currency is £ sterling.
1.

Accounting Policies

Basis of accounting
The financial statements are prepared under the historical cost convention and in accordance with the FRS 105 Financial Reporting Standard for Micro Entities (effective January 2016).
Tangible fixed assets
Tangible fixed assets, other than freehold land, are stated at cost or valuation less depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost or valuation of fixed assets, less their estimated residual value, over their expected useful lives on the following basis:
2.

Tangible fixed assets

Cost or Valuation Computer Equipment   Total
  £   £
At 01 November 2023 1,492    1,492 
Additions  
Disposals  
At 31 October 2024 1,492    1,492 
Depreciation
At 01 November 2023 597    597 
Charge for year 298    298 
On disposals  
At 31 October 2024 895    895 
Net book values
Closing balance as at 31 October 2024 597    597 
Opening balance as at 01 November 2023 895    895 

3.

Average number of employees

Average number of employees during the year was 1  (2023: 1).
2